Drug Topics
OCTOBER 17, 2024
The National Community Pharmacists Association surveyed over 4000 independent pharmacy owners and managers for their thoughts on the 10 drugs selected for Medicare price negotiations.
Pharmacy Times
OCTOBER 17, 2024
Retail pharmacies benefit from the shift from a volume-centric model to a value-centric approach that focuses on enhancing patient care, reducing pharmacist burnout, and leveraging technology to improve efficiency and expand the scope of pharmacy services.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 17, 2024
Cases of meningococcal disease currently exceed prepandemic levels.
STAT
OCTOBER 17, 2024
The nation’s three largest Medicare Advantage insurers increasingly refused to pay for rehabilitative care for seniors in the years after adopting sophisticated technologies to aid in their coverage decisions, a Senate investigation found. UnitedHealth Group, Humana, and CVS Health targeted denials among older adults who were requesting care in nursing homes, inpatient rehab hospitals, and long-term hospitals.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
OCTOBER 17, 2024
The country’s three largest Medicare Advantage (MA) insurers obstruct seniors’ ability to receive post-acute care, a scathing report from the U.S. | A report from Sen. Richard Blumenthal, D-Connecticut, found that the country's biggest Medicare Advantage insurers use artificial intelligence to control costs and deny prior auth claims.
STAT
OCTOBER 17, 2024
In the last two years, telehealth has gone all in on GLP-1s. Dozens of companies have started to offer the wildly popular obesity and diabetes medications, meeting patients who are flooding online for prescriptions that could help them lose as much as 20% of their body weight. The telehealth GLP-1 boom wouldn’t be possible without clinicians willing to write prescriptions for those hundreds of thousands of patients.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
OCTOBER 17, 2024
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You can also read Sandoz CEO Richard Saynor on what the 2024 conversation is missing and Bayer Pharmaceuticals COO Sebastian Guth on bad policy ideas.
Drug Topics
OCTOBER 17, 2024
In posters presented at the American College of Clinical Pharmacy 2024 Annual Meeting, researchers explored the implementation of collaborative care programs within various health systems.
STAT
OCTOBER 17, 2024
For three physicians, the changes were gradual, and then unmistakable, when UnitedHealth Group took over their practices. They lost control over their schedules, they were told to prioritize coding their patients’ illnesses , they felt like widgets. Those were the experiences of three former UnitedHealth doctors — Susan Baumgaertel, Michael Good, and Rubin Hirsch — who spoke at STAT’s annual summit in Boston on Wednesday.
Fierce Pharma
OCTOBER 17, 2024
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system innovation in the space as drugmakers sought to avoid the common pitfall | The 24-hour Parkinson's disease therapy crossed the FDA finish line after an initial manufacturing-related rejection last year and another snub in June.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 17, 2024
HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.
European Pharmaceutical Review
OCTOBER 17, 2024
In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA). What are the main advantages of EURneffy over similar treatments? EURneffy was determined by the European Medicines Agency (EMA) to be interchangeable with injection products given it provides the comparable exposures to epinephrine (adren
Pharmacy Times
OCTOBER 17, 2024
Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.
STAT
OCTOBER 17, 2024
Jazmin Evans was waiting on dialysis for four years before finally, on the Fourth of July last year, she received a kidney transplant. “Now I say the fireworks are for me,” said Evans, who was diagnosed with kidney disease when she was 17. She would have been waiting even longer had it not been for a shift, in 2021, in the way that physicians calculate kidney function for Black patients like her.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioPharm
OCTOBER 17, 2024
Through the collaboration, Merck will use Mestag’s proprietary RAFT platform to investigate the pathogenic role that fibroblasts play in inflammatory diseases.
STAT
OCTOBER 17, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. I had the unexpected opportunity to wake up a little too early today, not unlike the way Bristol Myers Squibb CEO Chris Boerner had the unexpected opportunity to testify in front of Bernie Sanders earlier this year.
pharmaphorum
OCTOBER 17, 2024
The first human skin atlas is helping researchers to understand how skin forms, the mechanisms behind disorders, and could usher in scarless healing
STAT
OCTOBER 17, 2024
For the last 20 years Alnylam Pharmaceuticals has converted Nobel-winning research on RNA-based gene-silencing into medicines, winning approvals for drugs delivered to the liver. That’s where some misfolded proteins are made, and in an increasingly diagnosed heart disease called ATTR cardiomyopathy, they eventually jam up muscles in the heart and contribute to heart failure.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
OCTOBER 17, 2024
Sage has launched another round of layoffs as it deals with the fallout of dropping a key pipeline drug for Alzheimer's and Parkinson's
STAT
OCTOBER 17, 2024
Veteran biotech executive Tony Coles has been the man behind the curtain of two multibillion-dollar acquisitions and many more boardroom discussions. But, publicly, he has arguably been just as active pushing the drug industry and other business leaders towards difficult conversations on corporate responsibility and race. Those conversations, he told the crowd at the STAT Summit in Boston Thursday, have been much more difficult.
Pharmacy Times
OCTOBER 17, 2024
Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.
STAT
OCTOBER 17, 2024
Why are biotech investors so interested in autoimmune disease? Who is behind the telehealth GLP-1 boom? And what were our favorite moments from the STAT Summit this week? We talk about all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about investors’ interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the invisible m
Fierce Pharma
OCTOBER 17, 2024
With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, younger people have become markedly
STAT
OCTOBER 17, 2024
The bad news didn’t come all at once for Blue Note Therapeutics, but a final denial from the Food and Drug Administration in January proved to be the final blow. In late 2023, after a rejection from the agency earlier in the year, Blue Note had made a last ditch attempt to convince the FDA that Attune, its mental health app for cancer patients, could fill an urgent unmet need.
Pharmacy Times
OCTOBER 17, 2024
This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.
STAT
OCTOBER 17, 2024
A coalition of unions, consumer groups and public interest organizations urged the Federal Trade Commission to challenge a $16.5 billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.
pharmaphorum
OCTOBER 17, 2024
NICE backs NHS use of Roche's Alecensa as first adjuvant therapy for ALK+ NSCLC, and peri-operative use of MSD's Keytruda for all-comer NSCLC patients
STAT
OCTOBER 17, 2024
People who rely on Medicaid continue to get medical care at high rates, and it’s presenting a growing challenge for the major health insurers who cover them. On Thursday, Elevance Health disclosed in its third quarter earnings release that its medical loss ratio — the amount of premium revenue it spent on medical care — was markedly higher than Wall Street analysts expected, sending its stock price into a tailspin.
Fierce Pharma
OCTOBER 17, 2024
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. | Eli Lilly is making a series of investments in China. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.
STAT
OCTOBER 17, 2024
Over the summer, the Food and Drug Administration announced the creation of the Rare Disease Innovation Hub to serve as a point of collaboration and connectivity between the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), patient organizations, and product innovators with the goal of ultimately improving outcomes for patients.
Drug Topics
OCTOBER 17, 2024
Findings from a collection of posters at ACCP underscore the critical role of community pharmacies in promoting health equity and providing high-quality, patient-centered care.
STAT
OCTOBER 17, 2024
Medicare is in trouble, and it’s largely the fault of the Medicare Advantage program that is run by private insurers, according to Donald Berwick, who ran Medicare during the Obama administration. More than half of people on Medicare are enrolled in private Medicare Advantage plans, and MA’s share of the market is growing fast. Medicare pays Medicare Advantage plans a set annual rate for each enrollee.
Fierce Healthcare
OCTOBER 17, 2024
Elevance Health fell short of Wall Street analysts' predictions, posting $1 billion in profit amid rising medical costs. | Elevance Health fell short of Wall Street analysts' predictions, posting $1 billion in profit amid rising medical costs.
Expert insights. Personalized for you.
211 
Let's personalize your content